RARE DISEASE
Metachromatic leukodystrophy
Metachromatic leukodystrophy
Metachromatic leukodystrophy
Synonyms: Arylsulfatase A deficiency, MLD
Synonyms: Arylsulfatase A deficiency, MLD
Synonyms: Arylsulfatase A deficiency, MLD
Drug discovery
9
drugs
With orphan designations
Overview
Metachromatic Leukodystrophy (MLD) is an autosomal recessive lysosomal storage disorder caused by deficient ARSA or PSAP gene activity, leading to sulfatide accumulation and progressive demyelination. Clinically, it manifests as neurodegeneration with motor decline, cognitive impairment, and psychiatric symptoms, classified into late infantile (most severe), juvenile, and adult-onset forms. Diagnosis relies on reduced arylsulfatase A activity, genetic testing, and MRI findings of white matter changes. No cure exists, but emerging therapies include gene therapy and hematopoietic stem cell transplantation (HSCT) for select patients [1][2][12].
Burden
High morbidity: Progressive loss of motor/cognitive function; 34% mortality in pediatric cohorts, with late infantile forms often fatal by age 5–8 [4][7].
Caregiver impact: Significant psychological/financial strain due to 24/7 care needs and ~$22,579/year/patient medical costs [4][15].
Diagnostic delays: >50% of leukodystrophy cases remain undiagnosed, complicating timely intervention [4][10].
Therapies
Supportive care: Physical/occupational therapy, seizure management, and nutritional support [6][14].
Disease-modifying: FDA-approved gene therapy (Lenmeldy®) for pre-symptomatic late infantile/juvenile MLD; HSCT for early-stage cases [12][16].
Experimental: Intrathecal enzyme replacement therapy (ERT), substrate reduction therapy, and pharmacological chaperones [3][8].
Categories: rare genetic diseases, rare inborn errors of metabolism, rare neurological diseases, rare ophthalmic disorders, rare transplant-related disorders
Research Papers
334 drug discovery papers about Metachromatic leukodystrophy, with 2 first-in-class and 7 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
334 drug discovery papers about Metachromatic leukodystrophy, with 2 first-in-class and 7 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-11 | A study on the quality of life and burden of informal caregivers of children with metachromatic leukodystrophy in Poland
Abstract Background Metachromatic leukodystrophy (MLD) is a rare, inherited lysosomal storage disorder caused by a deficiency in arylsulfatase A (ARSA), leading to sulfatide accumulation, demyelination, and progressive neurological decline. Without treatment, patients – particularly those with early-onset forms – typically lose the ability to walk or communicate within months of symptom onset, and life expectancy is markedly reduced, often below 10 years. Although MLD is likely underdiagnosed in Poland, prevalence may be higher than average. Early diagnosis and prompt intervention with gene therapy (arsa-cel) are critical, as neuronal damage is irreversible. This exploratory study aimed to characterise the clinical course of MLD in Poland and assess the quality of life and financial well-being of caregivers. Results The study included 13 MLD patients and 28 caregivers. The most common forms were late-infantile (46.2%) and early-juvenile (38.5%). Most patients were classified as GMFC-MLD stage 6 (53.8%) and ELFC-MLD stage 4 (69.2%). Common symptoms included spasticity (84.6%), walking difficulties (84.6%), and speech disorders (69.2%). The mean age at diagnosis was 4.8 years, with 69.2% of caregivers reporting that delayed diagnosis adversely impacted the child’s health. Caregivers were predominantly female (67.9%) and reported high caregiving demands (mean = 35.7 h/week). WHOQOL-BREF scores exceeded medians for caregivers of people with rare diseases across all domains. Financial well-being was strongly correlated with physical health ( r = 0.636, p < 0.001) and psychological health ( r = 0.717, p < 0.001). Only 14.3% of MLD caregivers received psychological counselling at diagnosis, though 92.3% received financial support. Gene therapy was reported in 15.4% of cases; most patients received multiple forms of rehabilitative therapy. Conclusion MLD in Poland is characterised by early-onset, rapidly progressing forms that lead to severe disability and impose significant burdens on families. Delayed diagnosis was commonly reported in this cohort, with many caregivers indicating that it had negatively affected the child’s health and limited timely access to potentially disease-modifying treatments. Despite intensive caregiving responsibilities, many caregivers report a relatively preserved quality of life, especially when financial support is available. While these exploratory findings should be interpreted with caution, they support the need for improved early detection and coordinated care for individuals with MLD. Within this broader context, systematic newborn screening in Poland may facilitate earlier diagnosis and timely access to gene therapy, potentially improving patient outcomes and reducing the long-term burden on families and the healthcare system. Clinical trial number Not applicable
2026-08-03 | Gene therapy for rare diseases marks a new era in precision medicine: Insights from clinical trials
Gene therapy represents an important advance in the treatment of rare diseases, offering precise and transformative therapeutic strategies. As many rare diseases are associated with well-defined genetic variants, they represent ideal candidates for targeted genetic interventions. The substantial unmet medical need associated with rare diseases has driven growing interest in gene therapy, with more than 300 clinical trials reported to date. The aim of this study was to evaluate the current evidence on gene therapy for rare diseases by examining therapeutic strategies, target diseases, clinical progress, clinical outcomes, and emerging research trends. Several approved therapies, including those for hemophilia B, spinal muscular atrophy, metachromatic leukodystrophy, and Wiskott–Aldrich syndrome, have demonstrated the clinical potential of gene therapy. Clinical evidence suggests that gene-based therapies in the management of rare diseases can achieve sustained functional benefits, reduce disease-related complications, and lessen dependence on long-term replacement or supportive treatments. However, challenges in ethical considerations, regulatory requirements, manufacturing complexity, treatment costs, and limited patient access remain. Continued clinical evaluation is essential to further establish long-term safety and effectiveness. Advances in gene therapy technologies and clinical applications continue to expand therapeutic opportunities for rare diseases while supporting the broader development of precision medicine.
2026-07-22 | Design and application of prime editing to target ARSA P426L mutation in a metachromatic leukodystrophy patient
Metachromatic leukodystrophy (MLD) is a rare inherited lysosomal storage disease caused primarily by mutations in the Arylsulfatase A (ARSA) gene. Loss of functional ARSA leads to sulfatide accumulation, causing demyelination in the peripheral and central nervous system. MLD presents in different clinical forms, which all eventually result in severe neurological decline and death. Currently available treatment options are limited. Enzyme replacement therapy (ERT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) may slow disease progression but do not offer a cure. Libmeldy was recently approved by the European Medicines Agency (EMA) as the first gene therapy for early-onset forms of MLD. However, the potential long-term risk of insertional mutagenesis remains a concern and requires ongoing evaluation. In this project we targeted the ARSA P426L mutation, one of the most common MLD-causing mutations in Europe. We used prime editing, a CRISPR-Cas9 based mechanism, which allows to introduce precise changes into the genome. The experiments were carried out in K562 cells and hematopoietic stem and progenitor cells (HSPCs). If the ARSA P426L mutation could be corrected ex vivo in patient-derived HSPCs prior to transplantation, this approach could offer a potentially curative treatment for patients who are currently lacking effective therapeutic options. Such a strategy would eliminate the need to find a matching donor for allogeneic HSCT, evade its side effects and avoid the risk of insertional mutagenesis associated with Libmeldy. Instead, it would restore physiological ARSA expression by precisely correcting the mutation at its endogenous locus. In K562 cells, we successfully introduced the ARSA P426L mutation using prime editing, achieving mean editing efficiencies of 1.88% with PE2 and 10.20% with PE3. However, no editing was detected in HSPCs of healthy donors. As a result, this study did not progress to target patient-derived HSPCs. Further investigations are needed to focus on optimizing the prime editing mechanism as well as related components in order to achieve higher editing efficiency. Also research about target site specific limitations for prime editing should be closely monitored and taken into account when planning for future projects. Although editing of the ARSA P426L locus was not successful, the high efficiency to induce the IL2RG c.458T>C mutation in HSPCs, which was used as a proof of concept, supports the general feasibility of prime editing based gene therapy approaches.
2026-02-03 | Prosaposin in CNS health and disease, metabolic stress and exercise adaptation.
Prosaposin (PSAP), a highly conserved lysosomal protein and precursor of saposins A-D, has emerged as a key regulator of cellular and central nervous system (CNS) homeostasis. Disrupted PSAP trafficking may lead to amyloid protein aggregation with implications for neurodegenerative diseases. In Alzheimer's disease (AD) and Parkinson's disease (PD), PSAP shows altered expression patterns and pathological co-localization with amyloid aggregates. PSAP variants are linked to multiple neurodegenerative diseases, including synucleinopathies, Gaucher's disease, and metachromatic leukodystrophy. Its levels are elevated in blood and cerebrospinal fluid in some individuals with AD or PD and are upregulated by stress conditions such as nerve injury and cold adaptation, but not by exercise. Prosaptides, short peptides derived from PSAP, show protective effects in models of oxidative stress, CNS injury, and metabolic disorders. Pharmacological stabilization of PSAP interactions with progranulin has shown promise in neurodegenerative disease models. These findings suggest PSAP plays an important role in maintaining brain health and may hold therapeutic potential. Here, we provide a comprehensive overview of PSAP's role in CNS health and disease, metabolic stress, and exercise adaptation.
2025-12-24 | Effectiveness and Safety of Intravenous Administration of Mesenchymal Stem Cells Overexpressing Arylsulfatase A for the Treatment of Metachromatic Leukodystrophy in a Pig Model
This study evaluated intravenous administration of allogeneic mesenchymal stem cells (MSCs) transduced with AAV9-ARSA to pigs. The MSCs were modified to overexpress human arylsulfatase A (ARSA). Thirty-five days after treatment, ARSA activity significantly increased in CNS tissues. No hepatotoxicity or systemic inflammation was observed. The results confirm the safety and efficacy of this MSC-based gene therapy for metachromatic leukodystrophy (MLD).
2026-08-11 | A study on the quality of life and burden of informal caregivers of children with metachromatic leukodystrophy in Poland
Abstract Background Metachromatic leukodystrophy (MLD) is a rare, inherited lysosomal storage disorder caused by a deficiency in arylsulfatase A (ARSA), leading to sulfatide accumulation, demyelination, and progressive neurological decline. Without treatment, patients – particularly those with early-onset forms – typically lose the ability to walk or communicate within months of symptom onset, and life expectancy is markedly reduced, often below 10 years. Although MLD is likely underdiagnosed in Poland, prevalence may be higher than average. Early diagnosis and prompt intervention with gene therapy (arsa-cel) are critical, as neuronal damage is irreversible. This exploratory study aimed to characterise the clinical course of MLD in Poland and assess the quality of life and financial well-being of caregivers. Results The study included 13 MLD patients and 28 caregivers. The most common forms were late-infantile (46.2%) and early-juvenile (38.5%). Most patients were classified as GMFC-MLD stage 6 (53.8%) and ELFC-MLD stage 4 (69.2%). Common symptoms included spasticity (84.6%), walking difficulties (84.6%), and speech disorders (69.2%). The mean age at diagnosis was 4.8 years, with 69.2% of caregivers reporting that delayed diagnosis adversely impacted the child’s health. Caregivers were predominantly female (67.9%) and reported high caregiving demands (mean = 35.7 h/week). WHOQOL-BREF scores exceeded medians for caregivers of people with rare diseases across all domains. Financial well-being was strongly correlated with physical health ( r = 0.636, p < 0.001) and psychological health ( r = 0.717, p < 0.001). Only 14.3% of MLD caregivers received psychological counselling at diagnosis, though 92.3% received financial support. Gene therapy was reported in 15.4% of cases; most patients received multiple forms of rehabilitative therapy. Conclusion MLD in Poland is characterised by early-onset, rapidly progressing forms that lead to severe disability and impose significant burdens on families. Delayed diagnosis was commonly reported in this cohort, with many caregivers indicating that it had negatively affected the child’s health and limited timely access to potentially disease-modifying treatments. Despite intensive caregiving responsibilities, many caregivers report a relatively preserved quality of life, especially when financial support is available. While these exploratory findings should be interpreted with caution, they support the need for improved early detection and coordinated care for individuals with MLD. Within this broader context, systematic newborn screening in Poland may facilitate earlier diagnosis and timely access to gene therapy, potentially improving patient outcomes and reducing the long-term burden on families and the healthcare system. Clinical trial number Not applicable
2026-08-03 | Gene therapy for rare diseases marks a new era in precision medicine: Insights from clinical trials
Gene therapy represents an important advance in the treatment of rare diseases, offering precise and transformative therapeutic strategies. As many rare diseases are associated with well-defined genetic variants, they represent ideal candidates for targeted genetic interventions. The substantial unmet medical need associated with rare diseases has driven growing interest in gene therapy, with more than 300 clinical trials reported to date. The aim of this study was to evaluate the current evidence on gene therapy for rare diseases by examining therapeutic strategies, target diseases, clinical progress, clinical outcomes, and emerging research trends. Several approved therapies, including those for hemophilia B, spinal muscular atrophy, metachromatic leukodystrophy, and Wiskott–Aldrich syndrome, have demonstrated the clinical potential of gene therapy. Clinical evidence suggests that gene-based therapies in the management of rare diseases can achieve sustained functional benefits, reduce disease-related complications, and lessen dependence on long-term replacement or supportive treatments. However, challenges in ethical considerations, regulatory requirements, manufacturing complexity, treatment costs, and limited patient access remain. Continued clinical evaluation is essential to further establish long-term safety and effectiveness. Advances in gene therapy technologies and clinical applications continue to expand therapeutic opportunities for rare diseases while supporting the broader development of precision medicine.
2026-07-22 | Design and application of prime editing to target ARSA P426L mutation in a metachromatic leukodystrophy patient
Metachromatic leukodystrophy (MLD) is a rare inherited lysosomal storage disease caused primarily by mutations in the Arylsulfatase A (ARSA) gene. Loss of functional ARSA leads to sulfatide accumulation, causing demyelination in the peripheral and central nervous system. MLD presents in different clinical forms, which all eventually result in severe neurological decline and death. Currently available treatment options are limited. Enzyme replacement therapy (ERT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) may slow disease progression but do not offer a cure. Libmeldy was recently approved by the European Medicines Agency (EMA) as the first gene therapy for early-onset forms of MLD. However, the potential long-term risk of insertional mutagenesis remains a concern and requires ongoing evaluation. In this project we targeted the ARSA P426L mutation, one of the most common MLD-causing mutations in Europe. We used prime editing, a CRISPR-Cas9 based mechanism, which allows to introduce precise changes into the genome. The experiments were carried out in K562 cells and hematopoietic stem and progenitor cells (HSPCs). If the ARSA P426L mutation could be corrected ex vivo in patient-derived HSPCs prior to transplantation, this approach could offer a potentially curative treatment for patients who are currently lacking effective therapeutic options. Such a strategy would eliminate the need to find a matching donor for allogeneic HSCT, evade its side effects and avoid the risk of insertional mutagenesis associated with Libmeldy. Instead, it would restore physiological ARSA expression by precisely correcting the mutation at its endogenous locus. In K562 cells, we successfully introduced the ARSA P426L mutation using prime editing, achieving mean editing efficiencies of 1.88% with PE2 and 10.20% with PE3. However, no editing was detected in HSPCs of healthy donors. As a result, this study did not progress to target patient-derived HSPCs. Further investigations are needed to focus on optimizing the prime editing mechanism as well as related components in order to achieve higher editing efficiency. Also research about target site specific limitations for prime editing should be closely monitored and taken into account when planning for future projects. Although editing of the ARSA P426L locus was not successful, the high efficiency to induce the IL2RG c.458T>C mutation in HSPCs, which was used as a proof of concept, supports the general feasibility of prime editing based gene therapy approaches.
2026-02-03 | Prosaposin in CNS health and disease, metabolic stress and exercise adaptation.
Prosaposin (PSAP), a highly conserved lysosomal protein and precursor of saposins A-D, has emerged as a key regulator of cellular and central nervous system (CNS) homeostasis. Disrupted PSAP trafficking may lead to amyloid protein aggregation with implications for neurodegenerative diseases. In Alzheimer's disease (AD) and Parkinson's disease (PD), PSAP shows altered expression patterns and pathological co-localization with amyloid aggregates. PSAP variants are linked to multiple neurodegenerative diseases, including synucleinopathies, Gaucher's disease, and metachromatic leukodystrophy. Its levels are elevated in blood and cerebrospinal fluid in some individuals with AD or PD and are upregulated by stress conditions such as nerve injury and cold adaptation, but not by exercise. Prosaptides, short peptides derived from PSAP, show protective effects in models of oxidative stress, CNS injury, and metabolic disorders. Pharmacological stabilization of PSAP interactions with progranulin has shown promise in neurodegenerative disease models. These findings suggest PSAP plays an important role in maintaining brain health and may hold therapeutic potential. Here, we provide a comprehensive overview of PSAP's role in CNS health and disease, metabolic stress, and exercise adaptation.
2025-12-24 | Effectiveness and Safety of Intravenous Administration of Mesenchymal Stem Cells Overexpressing Arylsulfatase A for the Treatment of Metachromatic Leukodystrophy in a Pig Model
This study evaluated intravenous administration of allogeneic mesenchymal stem cells (MSCs) transduced with AAV9-ARSA to pigs. The MSCs were modified to overexpress human arylsulfatase A (ARSA). Thirty-five days after treatment, ARSA activity significantly increased in CNS tissues. No hepatotoxicity or systemic inflammation was observed. The results confirm the safety and efficacy of this MSC-based gene therapy for metachromatic leukodystrophy (MLD).
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
9 orphan drug designations for Metachromatic leukodystrophy, including 2 approved therapies.
9 orphan drug designations for Metachromatic leukodystrophy, including 2 approved therapies.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
recombinant fusion protein composed of a recombinant human arylsulfatase A (rhARSA) fused with a variable domain of the heavy chain of heavy chain-only antibody fragment targeting human transferrin | proteins | FDA | 2023-12-15 | — | Linno Pharmaceuticals, Inc. |
Adeno-associated virus serotype HSC15 expressing human arylsulfatase A | gene therapies | FDA | 2020-08-11 | — | Homology Medicines, Inc. |
Adeno-associated virus serotype HSC15 expressing human arylsulfatase A gene | gene therapies | EMA | 2020-06-26 | — | Propharma Group The Netherlands B.V. |
atidarsagene autotemcel [Lenmeldy] | cell therapies | FDA | 2018-03-08 | 2024-03-18 | Orchard Therapeutics Ltd. |
Recombinant human arylsulfatase A | proteins | EMA | 2010-11-26 | — | Takeda Pharmaceuticals International AG Ireland Branch |
recombinant human arylsulphatase A | proteins | FDA | 2008-04-11 | — | Shire Human Genetic Therapies |
arylsulfatase A (rhASA) | proteins | FDA | 2008-02-27 | — | Takeda Development Center Americas, Inc. |
Autologous CD34+ cells transfected with lentiviral vector containing the human arylsulfatase A cDNA [Libmeldy] | cell therapies | EMA | 2007-04-13 | 2020-12-18 | Orchard Therapeutics (Netherlands) B.V. |
Cebsulfase alfa | gene therapies | EMA | 2003-07-09 | — | Shire Pharmaceuticals Ireland Limited |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.